M&A activity in 2014 was dynamic, with more in vitro diagnostics (IVD) transactions compared to the previous two years combined. For 2015 to date, Worldwide IVD transactions (including instrument/reagent manufacturers, genome informatics and reference labs) are on par with 2014 activity although there has been a sharp decline in acquisitions in China. Also, EY’s Medtech Firepower Index shows steady growth in “firepower” – which EY defines as a company’s ability to do M&A based on the strength of its balance sheet -- since 2011, indicating high borrowing capacity and the potential for future transaction execution. In particular, the diagnostics market has seen an emergence of creative deal making between nontraditional partners specifically within oncology, NIPT and MRSA.
Meaningful Use Audits and healthcare compliance course offered to Physicians and healthcare professionals to explain the basics of Meaningful Use and HITECH audits. Course is general in nature as many Physicians and organizations are in different stages of meaningful use.
Precise Patient Registries: The Foundation for Clinical Research & Population...Health Catalyst
Join Dale Sanders as he shares his experience in developing disease registries, the history of patient registries, and the current design patterns in data engineering to create highly precise registries to support clinical research and population health management.
Topics:
*How the definition of the term “patient registry" has evolved from being associated with a federal- or state-mandated reporting requirement to a hospital or health system’s own population of patients, including device registries, drug registries, and procedure registries.
*Why engaging certain populations via group registries allows them to better understand their conditions and reach out for support from others who share their condition.
*Several untapped benefits of registries for disease and quality management.
*When to utilize patient registries to guide decision-making and drive change, especially at the point of care.
*Which of the critical steps to building a disease registry is most important.
*The keys to winning organizational support in order to implement a successful registry initiative.
*Precise patient registries play a significant role in the management of a broad variety of healthcare processes, including chronic diseases and conditions, as well as clinical research.
Understanding how registries are currently built vs. how they should be built is critical to the future of healthcare outcomes improvement, cost reduction, and translational research.
R&D
Drug Development
Diagnosis
Disease Prevention
Epidemic prediction
Remote Monitoring
Manufacturing
Marketing
Wrapping up
How is AI used in the pharmaceutical industry?
How does AI help in drug discovery?
Will AI lead to cheaper and better medications?
Artificial Intelligence in Health Care 247 Labs Inc
This presentation was shown at the Artificial Intelligence in Health Care event in Toronto Nov 16 2017. The discussion was to introduce various applications of artificial intelligence and machine learning in the health care field.
Meaningful Use Audits and healthcare compliance course offered to Physicians and healthcare professionals to explain the basics of Meaningful Use and HITECH audits. Course is general in nature as many Physicians and organizations are in different stages of meaningful use.
Precise Patient Registries: The Foundation for Clinical Research & Population...Health Catalyst
Join Dale Sanders as he shares his experience in developing disease registries, the history of patient registries, and the current design patterns in data engineering to create highly precise registries to support clinical research and population health management.
Topics:
*How the definition of the term “patient registry" has evolved from being associated with a federal- or state-mandated reporting requirement to a hospital or health system’s own population of patients, including device registries, drug registries, and procedure registries.
*Why engaging certain populations via group registries allows them to better understand their conditions and reach out for support from others who share their condition.
*Several untapped benefits of registries for disease and quality management.
*When to utilize patient registries to guide decision-making and drive change, especially at the point of care.
*Which of the critical steps to building a disease registry is most important.
*The keys to winning organizational support in order to implement a successful registry initiative.
*Precise patient registries play a significant role in the management of a broad variety of healthcare processes, including chronic diseases and conditions, as well as clinical research.
Understanding how registries are currently built vs. how they should be built is critical to the future of healthcare outcomes improvement, cost reduction, and translational research.
R&D
Drug Development
Diagnosis
Disease Prevention
Epidemic prediction
Remote Monitoring
Manufacturing
Marketing
Wrapping up
How is AI used in the pharmaceutical industry?
How does AI help in drug discovery?
Will AI lead to cheaper and better medications?
Artificial Intelligence in Health Care 247 Labs Inc
This presentation was shown at the Artificial Intelligence in Health Care event in Toronto Nov 16 2017. The discussion was to introduce various applications of artificial intelligence and machine learning in the health care field.
AI in Healthcare: From Hype to Impact (updated)Mei Chen, PhD
The primary goal of this workshop is to help health professionals gain a critical understanding of the various types of AI technologies available so they can make wise decisions and invest AI for healthcare improvement.
Artificial Intelligence (AI) is shaping and reshaping every industry under the sun. The Healthcare industry is not any exception.
In this presentation, I have discussed the basics of AI as well as how it is being used in various branches of the healthcare industry. I presented this topic in my departmental seminar in October 2021 and received appreciation as well as positive feedback in this regard.
Precision Medicine: Four Trends Make It PossibleHealth Catalyst
When realized, the promise of precision medicine (to specifically tailor treatment to each individual) stands to transform healthcare for the better by delivering more effective, appropriate care. To date, to achieve precision medicine, health systems have faced financial, data management, and interoperability barriers. Current trends in healthcare, however, will give researchers and clinicians the quality and breadth of health data, biological information, and technical sophistication to overcome the challenges to achieving precision medicine.
Four notable trends in healthcare will bolster to growth of precision medicine in the coming years:
Decision support methods harness the power of the human genome.
Healthcare leverages big data analytics and machine learning.
Reimbursement methods incentivize health systems to keep patients well.
Emerging tools enable more data, more interoperability.
Medical coding is the process of transforming transcribed data into set of numerical codes using a system of numbers to represent various medical problems, (diagnoses), and treatments (procedures
From traffic routing to self-driving cars, Alexa to Siri, AI’s reach is extending into all areas of life, including healthcare. Join Kimberley to learn more about how AI is being used now, and will be used in the near future, to facilitate provider-patient communication, mine medical records, assess patients, predict illness, suggest treatments, and so much more.
The Science of Launching and Achieving Growth in Oncologyaccenture
We have conducted research to understand how oncology companies are responding to New science, more treatment choices and changing economics. Visit https://accntu.re/2Jn72wq to learn our key takeaways for launching and achieving growth in oncology.
Drug discovery and development is a long and expensive process over time has notoriously bucked Moore's law that it now has its own law called Eroom's Law named after it (the opposite of Moore). It is estimated that the attrition rate of drug candidates is up to 96% and the average cost to develop a new drug has reached almost $2.5 billion in recent years. One of the major causes for the high attrition rate is drug safety, which accounts for 30% of drug failures. Even if a drug is approved in market, it could be withdrawn due to safety problems. Therefore, evaluating drug safety extensively as early as possible becomes all the more important to accelerate drug discovery and development. This talk provides a high-level overview of the current process of rational drug design that has been in place for many decades and covers some of the major areas where the application of AI, Deep learning and ML based techniques have had the most gains. Specifically, this talk covers a variety of drug safety related AI and ML based techniques currently in use which can generally divided into 3 main categories: 1. Classification 2. Regression 3. Read-across. The talk will also cover how by using a hierarchical classification methodology you can simplify the problem of assessing toxicity of any given chemical compound. We will also address recent progress of predictive models and techniques built for various toxicities. It will also cover some publicly available databases, tools and platforms available to easily leverage them. We will also compare and contrast various modeling techniques including deep learning techniques and their accuracy using recent research. Finally, the talk will also address some of the remaining challenges and limitations yet to be addressed in the area of drug safety assessment.
Chronic illness: 75% of health system costs in North America
* Reimbursement models & care pathways focused
on disease management will continue to escalate
Our latest #EY CFO study, Partnering for performance Part 5: the CFO and the chief executive officer (CEO), examines how the CFO’s relationship with their CEO has changed, and joint commitments required to strengthen their alliance. The study is based on a survey of 652 CFOs and interviews with CFOs and CEOs, and covers how leading CFOs and CEOs are partnering together on digital, M&A decisions, performance measurement and operating model redesign. To learn more visit: http://goo.gl/7dnWi6
EY Valuation & Business Modelling - Luxembourg officeeyluxembourg
The need for transparent and robust valuations to support corporate transactions and to meet regulatory requirements has increased. Justifying the value of assets and liabilities has grown more complex and is increasingly critical for businesses. Our experienced valuation professionals ask the right questions and help you find the right answers.
AI in Healthcare: From Hype to Impact (updated)Mei Chen, PhD
The primary goal of this workshop is to help health professionals gain a critical understanding of the various types of AI technologies available so they can make wise decisions and invest AI for healthcare improvement.
Artificial Intelligence (AI) is shaping and reshaping every industry under the sun. The Healthcare industry is not any exception.
In this presentation, I have discussed the basics of AI as well as how it is being used in various branches of the healthcare industry. I presented this topic in my departmental seminar in October 2021 and received appreciation as well as positive feedback in this regard.
Precision Medicine: Four Trends Make It PossibleHealth Catalyst
When realized, the promise of precision medicine (to specifically tailor treatment to each individual) stands to transform healthcare for the better by delivering more effective, appropriate care. To date, to achieve precision medicine, health systems have faced financial, data management, and interoperability barriers. Current trends in healthcare, however, will give researchers and clinicians the quality and breadth of health data, biological information, and technical sophistication to overcome the challenges to achieving precision medicine.
Four notable trends in healthcare will bolster to growth of precision medicine in the coming years:
Decision support methods harness the power of the human genome.
Healthcare leverages big data analytics and machine learning.
Reimbursement methods incentivize health systems to keep patients well.
Emerging tools enable more data, more interoperability.
Medical coding is the process of transforming transcribed data into set of numerical codes using a system of numbers to represent various medical problems, (diagnoses), and treatments (procedures
From traffic routing to self-driving cars, Alexa to Siri, AI’s reach is extending into all areas of life, including healthcare. Join Kimberley to learn more about how AI is being used now, and will be used in the near future, to facilitate provider-patient communication, mine medical records, assess patients, predict illness, suggest treatments, and so much more.
The Science of Launching and Achieving Growth in Oncologyaccenture
We have conducted research to understand how oncology companies are responding to New science, more treatment choices and changing economics. Visit https://accntu.re/2Jn72wq to learn our key takeaways for launching and achieving growth in oncology.
Drug discovery and development is a long and expensive process over time has notoriously bucked Moore's law that it now has its own law called Eroom's Law named after it (the opposite of Moore). It is estimated that the attrition rate of drug candidates is up to 96% and the average cost to develop a new drug has reached almost $2.5 billion in recent years. One of the major causes for the high attrition rate is drug safety, which accounts for 30% of drug failures. Even if a drug is approved in market, it could be withdrawn due to safety problems. Therefore, evaluating drug safety extensively as early as possible becomes all the more important to accelerate drug discovery and development. This talk provides a high-level overview of the current process of rational drug design that has been in place for many decades and covers some of the major areas where the application of AI, Deep learning and ML based techniques have had the most gains. Specifically, this talk covers a variety of drug safety related AI and ML based techniques currently in use which can generally divided into 3 main categories: 1. Classification 2. Regression 3. Read-across. The talk will also cover how by using a hierarchical classification methodology you can simplify the problem of assessing toxicity of any given chemical compound. We will also address recent progress of predictive models and techniques built for various toxicities. It will also cover some publicly available databases, tools and platforms available to easily leverage them. We will also compare and contrast various modeling techniques including deep learning techniques and their accuracy using recent research. Finally, the talk will also address some of the remaining challenges and limitations yet to be addressed in the area of drug safety assessment.
Chronic illness: 75% of health system costs in North America
* Reimbursement models & care pathways focused
on disease management will continue to escalate
Our latest #EY CFO study, Partnering for performance Part 5: the CFO and the chief executive officer (CEO), examines how the CFO’s relationship with their CEO has changed, and joint commitments required to strengthen their alliance. The study is based on a survey of 652 CFOs and interviews with CFOs and CEOs, and covers how leading CFOs and CEOs are partnering together on digital, M&A decisions, performance measurement and operating model redesign. To learn more visit: http://goo.gl/7dnWi6
EY Valuation & Business Modelling - Luxembourg officeeyluxembourg
The need for transparent and robust valuations to support corporate transactions and to meet regulatory requirements has increased. Justifying the value of assets and liabilities has grown more complex and is increasingly critical for businesses. Our experienced valuation professionals ask the right questions and help you find the right answers.
Blockchain in capital markets and structured financeEY
The blockchain concept has generated a considerable amount of attention within capital markets, with discussions expanding into practical applications in securitization. Explore considerations around the application of blockchain in capital markets and the proposed applications of blockchain in structured finance.
Alliance One Detectives And Private InvestigatorsAlliance One
Alliance One Detectives is the best agency for corporate investigation in Mumbai. We provide the necessary data to give you the edge in your business dealings and investments.
Our investigations can assist in cases of:
Acquisitions and Mergers
A due diligence report can be produced to investigate the validity of a business aquisition or merger price.
Arbitration Proceedings
Alliance One Detectives can provide information to help settle arbitration proceedings quickly.
Competitive Intelligence
Our due diligence reports can provide you with competitive intelligence allowing you to make more accurate strategic decisions
Civil and Criminal Litigation
Alliance One Detectives can provide detailed information to assist in Civil and Criminal cases.
Corporate and Financial Transactions
Alliance One Detectives’ financial due diligence checks can ensure peace of mind to potential buyers by analysing and validating all the financial, commercial, operational and strategic assumptions being made.
Potential Employee Checks
Alliance One Detectives’s potential employee checks give you all the information you need before bringing someone new into your team.
Financial Information including CCJ’s, Bankruptcy and Credit Checks
Alliance One Detectives can provide comprehensive information on a person’s credit history and assets.
Fraud Prevention and Detection
Alliance One Detectives’ Fraud Prevention checks include confidential investigation of suspicious activities by employees, management, suppliers and clients.
Investments (Business and Personal)
Alliance One Detectives aim to enhance our clients’ investment success by providing intelligence on key risks and benefits associated with each investment.
Pre-sue Reports
If all other possible payment arrangements have been exhausted, bringing a debtor to court may be the only remaining option – in such cases as these, a pre-sue report can provide details to clients as to whether or not a debtor is able to pay.
Tracing Debtors
Alliance One Detectives offer an efficient debtor tracing service, tracking down individuals and companies which have moved premises and changed trading names.
Material Contracts and Agreements
A due diligence report examine the quality of the assets and potential buyer/seller to ensure a safe transaction
Asset Tracing
Alliance One Detectives’ asset tracing reports can uncover someone’s hidden assets, however hard they may try to hide them. These may be in the form of corporate investments, shares, trust funds, undisclosed accounts or loans, possibly abroad.
Best Fraud Investigation Detectives in Mumbai
Alliance One Detectives‘ Insurance fraud investigation team are highly trained at detecting and preventing insurance fraud. We have been involved in many high profile and complex investigations in the past from exaggerating claims to deliberately causing accidents or damage.
Materi Workshop Legal Due Diligence (LDD) yang di selenggarakan oleh EMLI Training. Materi di sampaikan oleh Bapak Dendi Adisuryo, beliau adalah Partner at ADCO Attorneys at Law.
Watch full webinar here: http://www.firmex.com/Due-Diligence-Best-Practices-and-Pitfalls-sign-up/
LOIs and NDAs signed. Now art meets science with the legal, financial and strategic review of the business. How do you test the value proposition and identify potential risks? Select the best tools to streamline the process? And prepare for regulatory and legal compliance issues arising from legislation like FCPA? Learn what it takes to avoid pitfalls that plague even the most experienced due diligence experts.
The Six Highest Performing B2B Blog Post FormatsBarry Feldman
If your B2B blogging goals include earning social media shares and backlinks to boost your search rankings, this infographic lists the size best approaches.
Third Party Due Diligence - Know Your Third Party - EY IndiaErnst & Young
Third party due diligence, forensic data analytics and frequent compliance audits form the basis of a strong monitoring system. For more details, visit http://bit.ly/1RQuEGB.
Unclaimed property historic litigation and legislation May 8, 2017Debera Salam, CPP
Here's the presentation handout and replay link to the Ernst & Young LLP webcast on May 8 about the current legislative and litigation environment affecting unclaimed property.
Due Diligence - What You Don’t Find Out Will Hurt YouNow Dentons
This presentation focuses on the details of the due dilligence process. It covers the definition and role of due dilligence, provides a legal due diligence checklist and gives an overview of key due dilligence points and mining considerations.
mHealth Israel_Future of Integrated Individualized Healthcare_Roche DiagnosticsLevi Shapiro
Presentation by Alexandra Eberhard, Sr. Director, Global Business Development, Roche Diagnostics on the "Future of Integrated Individualized Healthcare". Includes background about Roche Diagnostics and investments in innovation. Overview of Roche products and solutions with a portfolio covering the entire spectrum of diagnostics users. Emphasis on the triple aim of healthcare- The power of data and technology to enable the transformation from volume- to value-based healthcare. Interest in data for Pharma - drive more efficient R&D; DIA - develop novel patient care Dx solutions. Focus on the needs of labs, physicians & payers for better patient health. A suite of digital solutions that improve clinical & business outcomes. Suite of solutions to optimize the lab. Translating data into insights to achieve financial goals. A move from volume- to value-based care. New opportunities in the disease continuum- Holistic solutions approach. Expanding the focus towards earlier in the patient journey. Doing now what patients need next. Contact Alexandra Vallon-Eberhard, PhD MBA; Sr. Director Global Business Development; Diagnostics Lead for Innovation in Israel; Based in Basel, Switzerland; Email: alexandra.vallon_eberhard@roche.com
Viral Clearance Testing Market Will Hit Big Revenues in Futuretonnystark14
The Global Viral Clearance Testing market is projected to grow at a CAGR of around 20.10% during the forecast period, i.e., 2023-28. With expanding consumer appetite for biopharmaceutical products, strict regulatory control, and a surge in viral infection rates globally, the market has grown significantly in the past decade, and this trend is expected to continue in the coming year. The prevalence of several viral infections, such as Coronavirus, H1N1, and others, is growing globally, causing companies to manufacture & develop drugs. Due to the government's stringent regulations, this testing is an essential step to ensure the safety & efficacy of biopharmaceutical products, which may be contaminated with viruses, driving demand for this testing & propelling its market expansion.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
Real world data is no longer just for those trained in health economics and outcomes research — it can and will touch everyone in the pharma/healthcare space.
CBI asked industry's foremost RWD thought leaders a variety of questions to better understand how bio/pharmaceutical teams can collaborate and capture data in an aggregated form to continue to improve the value of products in development with real world, real-time data.
Real World Data - The New Currency in HealthcareJohn Reites
White paper published in June 2015 by CBI Life Sciences with interview insights from John Reites.
Real World Data (RWD) have become the bio/pharmaceutical industry’s treasure trove for information to inspire stakeholder decision-making. As an industry, professionals have increasingly been looking to RWD to not only assess the bene ts and risks of new medicines in clinical and real world settings, but also as a way to advise healthcare reimbursement decisions worldwide.
09 CeoMeeting- Session 4- Medicines for MalariaMLSCF
Session 4: Health & Wellness
Title: The Changing Face Of Healthcare:
Where Are The Opportunities?
Special Speaker: Dr Chris Hentschel, Medicines for Malaria Venture
The value of early asset development and commercializationCello Health
Worldwide pharmaceutical R&D spend is increasing each year, and the competition for a share of that investment is becoming fiercer. Companies need to demonstrate the potential value of their asset in commercial as well as scientific and clinical terms.
The slides in this deck define and identify value from a financial, clinical and commercial perspective while also exploring how to derive value for patients.
10 Most Innovative CRO’s To Watch In 2022.pdfinsightscare
During the COVID-19 pandemic, if clinicians, healthcare service-providing staff, nurses, and doctors were battling at the forefront, then the Clinical Research Organizations (CROs) have been working hard
Submission Id a4067a7f-7103-4a7e-b9a1-88b9598eaf0243 SIM.docxdavid4611
Submission Id: a4067a7f-7103-4a7e-b9a1-88b9598eaf02
43% SIMILARITY SCORE 8 CITATION ITEMS 12 GRAMMAR ISSUES
Int ernet Source 14%
Inst it ut ion 29%
Nanah Kamara
StatisticsInhealthcare (1).docx
Summary
838 Words
Healt h St at ist ics
Tit le: Healt h St at ist ics
Name: Nanah Kamara
Inst it ut e: GCU
Dat e: 06/09/2019
Describe t he applicat ion of st at ist ics in healt h care. Specifically discuss it s
significance t o qualit y, safet y, healt h promot ion, and leadership.
In healt hcare, we use st at ist ics in an effort t o improve healt hcare and keep pat ient s
safe. Healt h St at ist ics provide informat ion for underst anding, monit oring, improving
and planning t he use of resources t o improve t he lives of people, provide services and
promot e t heir well-being. St at ist ics are used in healt hcare for research, qualit y
improvement , inequalit ies in healt hcare, risk analysis, invent ory management and cost ,
resource ut ilizat ion, pat ient lengt h of st ay, pat ient sat isfact ion, clinical t rials,
morbidit y and mort alit y, effect s of new t reat ment s, measuring change, laborat ory
analysis, educat ion, and much more.
We are using st at ist ics in an effort t o improve healt hcare and keep pat ient s safe.
Healt h St at ist ics basically provide informat ion for underst anding, monit oring,
improving and planning t he use of resources t o improve t he lives of people, provide
services and promot e t heir well-being.
In healt h care, st at ist ics is used t o “ident ify pat ient care t rends using dat a, and
increase t he abilit y t o creat e and ut ilize evidence-based pract ice”. There are several
major uses of healt h st at ist ics. Healt h st at ist ics helps creat e fundament al knowledge
about t he healt h of populat ions; it provides informat ion t o guide healt h policy
Spelling mistake: Nanah Nanak
Student: Submitted to Grand Canyon University 1…
Student: Submitted to Grand Canyon University 1…
Student: Submitted to Grand Canyon University 2…
development , assessment , and evaluat ion.
St at ist ics have been ut ilized in healt hcare since at least t he 19t h cent ury. Florence
Night ingale used a st at ist ical approach t o decrease t he mort alit y rat e of Brit ish
t roops in Crimea. She was an innovat or in t he collect ion, t abulat ion, int erpret at ion, and
graphical display of descript ive st at ist ics and her met iculous records were a key t o
present day st at ist ical qualit y measurement (Sheingold& Hahn, 2014). Clara Bart on
applied t he same analysis in t he Unit ed St at es during t he Civil War. Louis Past eur
applied st at ist ics in his research of microbes and t he germ t heory t o creat e penicillin.
This evidence led t o t he wide-scale adopt ion led t o t he development of
past eurizat ion.
Influenza Pandemic is t he worst out break of disease in U.S. hist ory (1918) and in.
The theme for this quarter is momentum meets uncertainty. The upward trend in crude oil, natural gas, LNG and refined product prices that began in Q1 continued into Q2. Crude oil markets began the quarter just below $100/bbl and have closed below that level on only two days since late April. As we begin Q3, there are increasing concerns about the health of the global economy and how that might affect oil and gas demand.
Quarterly analyst themes of oil and gas earnings, Q1 2022EY
Financial questions continued to attract the most attention of the analyst community, with major focus on how companies will respond to the war in Ukraine, elevated commodity prices and improved cash flows. Strategic questions focused on how the changing geopolitical environment will affect capital allocation in the short and long term. Operationally, all eyes were on the capacity of companies to step up asset utilization and bring new projects to market quickly. Explore the latest EY quarterly analysts themes.
EY Price Point: global oil and gas market outlook, Q2 | April 2022EY
The theme for this quarter is rearrangement. The loss, or potential loss, of Russian oil and gas supplies is forcing producers, refiners and traders to rethink the flow of crude oil and refined products from the wellhead to the gas pump in light of sanctions, potential sanctions and the risk of reputational damage. Countries, companies and consumers will all be searching for ways to adapt, and the outcome of the race to bring alternatives to market could alter the global energy landscape for years to come.
It is likely crude oil and LNG prices will remain elevated for some time. The process of diverting Russian oil through countries unwilling to sanction it will take time and there is little indication OPEC members are willing (or able) to increase production to make up for the loss of Russian crude. Spare capacity sat at 3.7 mbpd at the end of 2021, just above where it was in January 2020. Currently, sanctioned Venezuelan and Iranian production (about 3 mbpd below their peak) could fill the gap, but political and commercial obstacles remain. At today’s prices, US shale production is attractive, but the fastest the industry has been able to grow is between 1mbpd and 2mbpd per year. The LNG infrastructure was already stretched before the war in Ukraine and there is little prosect of finding new supplies soon.
As the largest buyer of Russian energy, Europe will be the epicenter. There is a deeply embedded bias there in favor for renewable energy, and the current crisis is certain to result in an all-out effort to accelerate the build-out of wind and solar power. The capacity to add new green energy is limited though by the project pipeline and supply chains for solar panels and wind turbines, and it is likely that much of the shortfall will be made up with the new LNG infrastructure.
EY Price Point: global oil and gas market outlookEY
As the last quarter of the second pandemic year draws to a close, we continue to see heightened contrast
between the medical and economic points of view. While COVID-19 cases are close to their all-time highs, so
are equity prices, and a leading investment bank declared (on 2 December, 2021 after the Omicron outbreak in South Africa) that it was “optimistic about the possibility of a vibrant 2022.” When news of the variant hit in
late November, the markets were rocked by the prospect of yet another round of local mobility restrictions and
an interrupted return to normal international travel patterns, on top of the Biden Administration’s announced
release of 50 million barrels of crude from the US Strategic Petroleum Reserve. So far though, with OPEC
standing by its planned gradual return to normal production, oil prices have stabilized, albeit below where they
were in mid-November. Henry Hub prices, always at the mercy of the weather, responded predictably to a
warmer-than-normal early winter in the US, falling from US$6.60/MMBtu in early October to below
US$4.00/MMBtu by mid-December. In Europe and Asia, following a short reprieve at the start of the quarter,
piped natural gas prices have spiked again on concerns triggered by Russian troop buildups on the Ukraine
border and uncertainties surrounding the Nordstream 2 pipeline. Looking forward, OPEC and the U.S. Energy
Information Administration (EIA) in their last forecasts of the year both projected that 2022 oil demand would
be above what we saw in 2019. Although time will tell if those forecasts are realized and other events could
intervene, the response to new virus outbreaks is well-practiced and the trade-off between public health and
economic reality has tipped toward a cautiously optimistic view.
EY Price Point: global oil and gas market outlook, Q2 April 2021EY
The theme for this quarter is governed. Apparent market balance at prices that could be sustainable is the product of calculated choices by market leaders and the cooperation of those who follow them. Economics played their customary role as well, with capital scarcity in North America taking about 2 million barrels per day out of the market, about half of the remaining gap in demand. While inventories are close to their pre-COVID-19 levels, there is still uncertainty. The resolution of the pandemic is in sight, but timing is unclear. Vaccine distribution in the US is having an impact but Europe is struggling to contain a third wave of infections. The taps have opened on economic stimulus, but it remains to be seen if policymakers have done enough or if they have overshot the mark.
The shape of the crude oil forward curve has fundamentally changed since the end of the last quarter. In late December of last year, the Brent forward curve was gradually increasing while today, the curve is backwardated. This is a clear sign that the market sees a short-term dynamic that is disconnected from the medium-to-long-term fundamentals. The lasting impact of the COVID-19 pandemic remains to be seen. While many have opined that COVID-19 marks a turning point in energy transition, the IEA recently released a five-year forecast of oil demand that shows steady growth, albeit at rates that are below historical expectations.
Gas markets are a paradox. At the Henry Hub and at LNG destinations, demand grows, investment lags and prices will occasionally attract attention. Traders, so far though, are unconvinced and futures prices don’t indicate imminent scarcity at any link in the value chain.
EY Price Point: global oil and gas market outlookEY
We enter 2021 on a note of cautious optimism for global health, the world economy, and the oil and gas markets. The first weeks of December brought approval in the US and the UK of the first of several COVID-19 vaccines. The speed with which vaccine development occurred is unprecedented, but certainly welcome. In the weeks following the early November announcement of 90+% effectiveness by the manufacturer of the first approved vaccine, the price of WTI crude oil increased by US$10/bbl to US$48/bbl, the highest level since early March. Sustainability hasn’t returned yet, and whatever time it takes to get the world to normal, it will take even longer for normalization within the oil and gas markets. Inventories remain at historically high levels and, optimistically, it will take until April before inventory returns to levels observed in the preceding five years. That’s an estimate, and there has obviously been some difficulty properly calibrating the expectations of how balance will return and how long it will take. In late November, OPEC met to adjust its output plans because of the anemic rebound in demand. In mid-December, the IEA lowered its demand forecast for 2021 due mostly to continued sluggishness in aviation fuel demand.
A mild winter has interrupted a recovery in North American natural gas prices after a run-up motivated by curtailed capital expenditures, upstream activity and production. After an initial meltdown, with cargo cancellations and dramatic price reversal, LNG markets have made a remarkable comeback, and the spread between Asia and Henry Hub has reached a level we haven’t seen in almost three years. It may be the case that interruption in FIDs has brought us to the cusp of a balance that can support reliable returns.
EY Price Point: global oil and gas market outlook (Q4, October 2020)EY
Oil and gas prices have recovered steadily from their lows and are relatively stable, but that stability is supported by the combination of purposeful withholding of production by oil-producing countries and economic stress on upstream independents. Oil prices closed the quarter roughly where they started it, while refining spreads were down slightly. LNG spreads were substantially higher at the end of Q3 than they were at the beginning of the quarter but are still roughly half of what is generally thought of as sustainable.
Going forward, the market will be looking closely at how the economy and demand respond to new developments with respect to a potential COVID-19 vaccine and the US election.
EY Price Point: global oil and gas market outlookEY
As we close the second quarter of 2020, in most of Europe and Asia, the first (and hopefully last) wave of the COVID-19 crisis appears to be abating. In the parts of the US where the virus hit early, the profile has largely matched Europe’s, while in other parts, the urge to reopen businesses has trumped the desire to contain the virus and uncertainty looms. In the developing world, the crisis has just begun, but without the economic headroom and resources necessary to contain it. As the crisis unfolded, the effect on oil and gas demand has been predictable but difficult to gauge precisely and therefore difficult to manage.
Oil prices have crept up steadily as production has been curtailed through coordinated action (OPEC+) and because of economic reality (unconventional oil in North America). That trend has been subject to momentary spasms when bad news hit the market. It would be understandable if traders were nervous, and it seems that they are. Although nowhere near where it was at the peak of the crisis, option implied volatility is still at historically high levels. Gas markets, without the benefit of coordination on the supply side, continue to deal with the market implications of storage at or near capacity. Interfuel competition in power generation has always provided something of a floor, but those lows have been, and will continue to be, tested.
Zahl der Gewinnwarnungen steigt auf RekordniveauEY
Immer mehr deutsche börsennotierte Unternehmen müssen ihre eigenen Umsatz- oder Gewinnprognosen nach unten korrigieren. Im ersten Quartal stieg die Zahl der Prognosekorrekturen auf ein neues Rekordniveau: Insgesamt 77 Gewinn- oder Umsatzwarnungen wurden registriert.
Die Corona-Krise trifft auch die Versicherungsbranche mit voller Wucht. Die Versicherer rechnen mit weniger Neugeschäft. Jeder Fünfte mit Personalabbau und Prämienerhöhungen.
Liquidity for advanced manufacturing and automotive sectors in the face of Co...EY
With a global economy in crisis due to Covid-19 our liquidity and cash management deck for advanced manufacturing and
mobility companies looks at how these companies should best respond.
IBOR transition: Opportunities and challenges for the asset management industryEY
EY Wealth & Asset Management explores the practical implications and the way forward for the transition to the new risk-free rates. This presentation aims to help asset managers and asset owners explore IBOR transition strategies that are compliant and future-focused.
Fusionen und Übernahmen dürften nach der Krise zunehmenEY
Folgt auf die Corona-Krise ein M&A-Boom? Laut Capital Confidence Barometer von #EY hoffen 40 Prozent der deutschen Unternehmen auf sinkende Bewertungen von Übernahmekandidaten.
EY Price Point: global oil and gas market outlook, Q2, April 2020EY
The first quarter of this year has seen some extraordinary events. As if chronic oversupply, prices stuck below sustainable levels, the looming energy transition, and investor pressure to decarbonize weren’t enough, our industry now faces a dramatic, but hopefully temporary, downturn in demand as a result of the ongoing COVID-19 outbreak.
Our Global Chemical Industry Leader Frank Jenner explores the trends and drivers that will shape the chemical industry of tomorrow in our latest Chemical Market Outlook.
Die Geschäftslage im Mittelstand hat sich leicht verschlechtert, ist in den meisten Branchen aber weiter überwiegend gut - die Einstellungsbereitschaft sinkt.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
1. Trending or here to stay?
The impact of innovation on the
future of in vitro diagnostics (IVD)
Kristin Pothier, Head of Life Sciences
Parthenon-EY
27 July 2015
2. Page 2
M&A environment for global IVD/LS tools: annually
M&A activity in 2014 was dynamic, with more IVD transactions compared to the
previous two years combined; 2015 is on par with 2014 to date
0
10
20
30
40
50
60
70
80
90
2010 2011 2012 2013 2014 2015E*
NumberofM&Atransactions
Historical transactions
Forecast transactions (based on H1:15)
2010 2011 2012 2013 2014 2015*
Total transaction
value (US$b)^ US$10.2 US$17.5 US$7.6 US$18.4 US$25.8 US$5.5
Example
transactions
(Alphabetical)
► Clarient (GE)
► EMD Millipore
(Merck KGaA)
► Ion Torrent (Life
Technologies)
► Axis-Shield
(Alere)
► Beckman
Coulter
(Danaher)
► Phadia (Thermo
Fisher)
► BlueGnome
(Illumina)
► Dako (Agilent)
► Gen-Probe
(Hologic)
► IRIS (Danaher)
► BioFire
(bioMerieux)
► Ingenuity
Systems
(QIAGEN)
► Life
Technologies
(Thermo Fisher)
► Crescendo
(Myriad)
► OCD (Carlyle)
► Siemens Micro.
(Danaher)
► BRLI (OPKO)
► Foundation
Medicine
(Roche)
Worldwide IVD transactions (instrument/reagent manufacturers, genome informatics and reference labs), 2010-15
Sources: EY analysis, Capital IQ. *Includes transactions in H1:15 ^Note: transaction values available for 54% of total transactions
3. Page 3
Global medtech financial environment
The EY Medtech Firepower Index has grown steadily since 2011, indicating high
borrowing capacity and the potential for future transaction execution
Firepower (and change) of large-cap medtech* companies (US$10b market cap as of 17 July 2015)
Sources: Capital IQ, EY analysis. *Large-cap medtech includes N=26 medtech companies with 17 July 2015 market values >US$10b; does not include Baxter due to change in
valuation following major divestitures in 2014-15.
-40%
-30%
-20%
-10%
0%
10%
20%
30%
40%
0
50
100
150
200
250
2007 2008 2009 2010 2011 2012 2013 2014 2015
Large-capmedtechfirepower(US$b)
Firepower Change in firepower
EY Firepower
► A company’s ability to do M&A based on the strength of its balance sheet
► Market capitalization, cash equivalents and debt capacity provide this firepower
4. Page 4
Global IVD partnership environment: key trends
The diagnostics market has seen an emergence of creative deal making between
nontraditional partners specifically within oncology, NIPT and MRSA
Sources: Company press releases, GenomeWeb, Capital IQ, Cowen, Forbes, Fierce Biotech. *Flatiron acquired Altos outright.
3 key trends in
2014-15 IVD
partnerships
Deals were largely focused in
oncology, NIPT and infectious
disease (including MRSA)
Some deals incorporated multiple
pharma companies with the same
IVD partner
Nontraditional stakeholders are
starting to become more involved
5. Page 5
International perspective: M&A environment
Deal activity in 2015 is comparable to 2014; however, there has been a sharp
decline in acquisitions in China
Sources: EY analysis, Capital IQ. *Includes transactions in H1:15 (n=40); Other includes Latin America, Middle East and Africa.
Worldwide IVD transactions by target company headquarters, Jan 2010-Jun 2015
0
10
20
30
40
50
60
70
80
90
2010 2011 2012 2013 2014 2015*
NumberofM&Atransactions
Europe United States and Canada Asia/Pacific Other
6. Page 6
International Firepower Index
The Firepower Index grew across all regions from 2013-15, but the proportion of
firepower is growing in emerging markets (BRIC) at the expense of the US.
Medtech firepower by country/region (2011-15)
Sources: Capital IQ, EY analysis. Index includes N=325 medtech companies across select geographies
EY Firepower
► A company’s ability to do M&A based on the strength of its balance sheet
► Market capitalization, cash equivalents and debt capacity provide this firepower
61%
56%
18%
20%
6% 9%
9% 8%
5% 5%
0
50
100
150
200
250
300
350
400
450
500
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2011 2012 2013 2014 2015
Globalmedtechfirepower(US$b)
US/CAN EU BRIC JP APAC EMEA LATAM Total global firepower
7. Page 7
For more information:
Kristin Pothier, Head of Life Sciences
Kristin Ciriello Pothier
Partner and Managing Director
Parthenon-EY
Tel: +1 617 375 1384/+1 617 549 2779 (Mobile)
Email: kristin.pothier@ey.com
Education
► Kristin earned a BA in Biochemistry from Smith College and an MS in Epidemiology,
Health Management, and Maternal and Child Health from the Harvard School of
Public Health
Areas of focus
► Kristin has extensive experience in commercial and clinical strategy and due
diligence for both strategics and investors
► Core areas of focus include commercial and operational strategy and M&A diligence
in the clinical core laboratory, molecular diagnostics, life sciences tools and
services, reference lab strategy, point of care, and personalized medicine from a
diagnostics and a pharmaceutical perspective
► Kristin serves clients in all sectors of the global life sciences industry including
► Pharmaceutical and precision/personalized medicine access strategy
► Core clinical diagnostics and innovative diagnostics, including molecular, POC
and NGS
► Reference lab strategy including hospital lab, global core reference labs,
specialty labs, anatomical pathology, clinical trials, and personalized medicine
► Life sciences tools and lab services, including sample prep, biorepositories, MS,
sequencing and translational platforms
► Health IT strategies, including middleware development, digital pathology
incorporation, biomarker algorithms and patient journey development, for
institutions and companies
► Extensive clinical knowledge in oncology, cardiovascular, global health, prenatal
and infectious disease across the globe
EY experience
► Kristin has 20 years of experience in the life sciences industry
► Kristin leads the life sciences sector of Parthenon-EY serving clients in pharma,
biotech, diagnostics and life science tools, with a focus on company and investor
commercial strategy and M&A support for diagnostics, life science research and
pharmaceutical companies
► She is also the creator and leader of EY Precision Medicine™, and specializes in
diagnostics clinical laboratories, the developing platform and reference lab
strategies worldwide with on-the-ground experience in North America, South
America, EU, Asia and the Caribbean
► Kristin is a co-founder and leader of DxInsights, a nonprofit organization
designed to educate on the impact of diagnostics and precision medicine in
improving health care outcomes to the nation's health care communities
► Kristin is a noted speaker, workshop leader and writer with a strong industry
following. She develops numerous publications and delivers speaking
engagements at the most prolific industry meetings and symposia
Previous professional experience
► Prior to EY, Kristin was a partner and owner of Health Advances, where she
owned and managed the firm with four other partners. She developed and led
the Diagnostics and Life Sciences practice, a global practice focused on product
and service strategy, corporate strategy, health economics and deal diligence
► Kristin is also a founder of DxInsights, a nonprofit organization designed to
educate the nation's health care communities on the impact of diagnostics in
improving health care outcomes
► Earlier in her career, Kristin was a research scientist at Genome Therapeutics, at
the time the only commercial entity sequencing for the Human Genome Project,
and at Genzyme, as part of the technology development team developing
prenatal and cancer diagnostics for the Genzyme Genetics clinical laboratory
8. Page 8
Parthenon-EY Life Sciences Strategy Services
We are global strategy consultants with focus on commercial and growth strategy
across the life sciences continuum
Commercial brand strategyGrowth strategy
DiligencePipeline strategy
Proprietary databases | Global primary research | Dedicated life sciences teams | Life sciences thought leadership
Life Sciences
Strategy Services
► Portfolio optimization
► Acquisition target identification
► Early-stage asset development strategy
► Market opportunity assessment
► Commercial launch strategy
► Market development strategy
and execution
► Focused, issues-based
commercial diligence
► Forecast achievability
Regional Variations Necessitate Diverse Testing and Partner
Options
• LDTs
• Sample exchange
• Cepheid V1
• Genoptix
• LDTs
• Ipsogen
• ELITech
• Cepheid V1
• Cepheid V1
• Ipsogen
• Asuragen
• Genoptix
• MMD
• LDTs
• Ipsogen
• LDTs
• Sample exchange
FM Patient Flow: Pre-Presentation to Treatment
FM
Society
Presents to
Physician Diagnosed
with FM -
12%
Treatment -
78%
204K 159K
FM Suff
1.7M
Specialist*
Internist
&
Ortho
Tx
Diagnosing
Cycling
FM not fully
understood
Refer to Alt.
HCP
Suspicion of
Alt. Conditions
Inappropriate
Tx
Referred to
Alt. HCP
Switch HCPDrops Out
System
Symptoms
not
ControlledCycling
Alt. Tx / OTC
Pain
Persists
Research
Symptoms
Suspicion of
Condition
Patient Actions
Physician Actions
Patient Actions
Hospital
or
Clinic
From Patient Perspective
From Physician Perspective
Market Overview & Competitive Landscape
Target competes both with basic “do-all” labs, as well as other
small independents with similar test offerings.
Basic “Do-all” Labs Esoteric Hospital /
Academic Labs
Small Independents and
Local Hospitals
Highly Specialized Labs
Volume&DiversityofTests
Scientific Expertise & Capabilities
Competitive Landscape Key Segments
► Basic “Do-all” Labs
– Offer test menu of >1,000 tests, with
revenue and volume focused on routine
tests.
– Serve as reference labs for institutions with
no or limited lab capabilities.
– Largest players, however, are increasing
focus on esoteric tests (e.g., LabCorp ,
Quest).
► Esoteric Hospital / Academic Labs
– Offer >1,000 tests, with core business
focused on highly complex esoteric tests.
– Also serve as reference laboratories for
smaller institutions.
► Highly Specialized Labs
– Typically focus on a low to moderate
number of esoteric tests requiring scientific
expertise.
– May be focused on one specific therapeutic
area (e.g., Myriad in oncology).
► Small Independents and Local Hospitals
– Includes small independent labs with
limited menus of tests and local hospital
labs that only do routine tests and send out
more complex tests.
Target
Primary Competition